Prospects for personalized Helicobacter pylori eradication therapy. Pro et contra
- 作者: Simanenkov V.1, Alekseenko S.2
-
隶属关系:
- Mechnikov North-Western State Medical University
- The Far Eastern State Medical University
- 期: 卷 94, 编号 8 (2022)
- 页面: 935-939
- 栏目: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/111810
- DOI: https://doi.org/10.26442/00403660.2022.08.201787
- ID: 111810
如何引用文章
全文:
详细
The article is devoted to debatable aspects of Helicobacter pylori eradication therapy. The eradication cancer-preventive effects are considered. A negative comorbidity between H. pylori infection and such diseases as gastroesophageal reflux disease, inflammatory bowel disease and bronchial asthma has been described. The perspectives of populational, individualized and personalized strategies for H. pylori eradication therapy assessment are given. Recommendations for individualized H. pylori eradication strategy implementation in practical healthcare are proposed.
作者简介
Vladimir Simanenkov
Mechnikov North-Western State Medical University
编辑信件的主要联系方式.
Email: visimanenkov@mail.ru
ORCID iD: 0000-0002-1956-0070
д-р мед. наук, проф., проф. каф. внутренних болезней, клинической фармакологии и нефрологии ФГБОУ ВО «СЗГМУ им. И.И. Мечникова»
俄罗斯联邦, Saint PetersburgSergei Alekseenko
The Far Eastern State Medical University
Email: visimanenkov@mail.ru
ORCID iD: 0000-0003-1724-9980
д-р мед. наук, проф., зав. каф. госпитальной терапии ФГБОУ ВО ДВГМУ
俄罗斯联邦, Khabarovsk参考
- Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1(8336):1273-5.
- Sugano K, Tack J, Kuipers EJ, Graham DY. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353-67. doi: 10.1136/gutjnl-2015-309252
- Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. doi: 10.1136/gutjnl-2016-312288
- Ивашкин В.Т., Маев И.В., Лапина Т.Л., и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению инфекции Helicobacter pylori у взрослых. Росийский журнал гастроэнтерологии, гепатологии, колопроктологии. 2018;28(1):55-70 [Ivashkin VT, Mayev IV, Lapina TL, et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55-70 (in Russian)]. doi: 10.22416/1382-4376-2018-28-1-55-70
- Park JY, Herrero R. Recent progress in gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2021;50-51:101733. doi: 10.1016/j.bpg.2021.101733
- Бордин Д.С., Войнован И.Н., Эмбутниекс Ю.В., и др. Европейский регистр Helicobacter pylori (Hp-EuReg) как инструмент для оценки и улучшения клинической практики в Москве. Терапевтический архив. 2020;92(2):12-8 [Bordin DS, Voynovan IN, Embutnieks YuV, et al. European registry on Helicobacter pylori management (Hp-EuReg) as a tool to evaluate and improve clinical practice in Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(2):12-8 (in Russian)]. doi: 10.26442/00403660.2020.02.000567
- Reshetnyak VI, Burmistrov AI, Maev IV. Helicobacter pylori: Commensal, symbiont or pathogen? World J Gastroenterol. 2021;27(7):545-60. doi: 10.3748/wjg.v27.i7.545
- Lansdorp-Vogelaar I, Meester RGS, Laszkowska M, et al. Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. Best Pract Res Clin Gastroenterol. 2021;50-51:101735. doi: 10.1016/j.bpg.2021.101735
- Georgopoulos S, Papastergiou V. An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection. Expert Opin Pharmacother. 2021;22(6):729-41. doi: 10.1080/14656566.2020.1845649
- Tacconelli E, Carrara E, Savoldi A, et al. WHO Pathogens Priority List Working Group. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis. 2018;18(3):318-27. doi: 10.1016/S1473-3099(17)30753-3
- Moghadam MT, Chegini Z, Norouzi A, et al. Three-Decade Failure to the Eradication of Refractory Helicobacter pylori Infection and Recent Efforts to Eradicate the Infection. Curr Pharm Biotechnol. 2021;22(7):945-59. doi: 10.2174/1389201021666200807110849
- Oh JH, Kwon JG, Jung HK, et al. Functional Dyspepsia Research Group and Clinical Practice Guidelines Group Under the Korean Society of Neurogastroenterology and Motility. Clinical Practice Guidelines for Functional Dyspepsia in Korea. J Neurogastroenterol Motil. 2020;26(1):29-50. doi: 10.5056/jnm19209
- Gravina AG, Priadko K, Ciamarra P, et al. Extra-Gastric Manifestations of Helicobacter pylori Infection. J Clin Med. 2020;9(12):3887. doi: 10.3390/jcm9123887
- Zuo ZT, Ma Y, Sun Y, et al. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol. 2021;182(1):53-64. doi: 10.1159/000508330
- Marshall B. The future of Helicobacter pylori eradication: a personal perspective. Aliment Pharmacol Ther. 1997;11(Suppl. 1):109-15. doi: 10.1046/j.1365-2036.11.s1.14.x
- Li L, Tan J, Liu L, et al. Association between H. pylori infection and health Outcomes: an umbrella review of systematic reviews and meta-analyses. BMJ Open. 2020;10(1):e031951. doi: 10.1136/bmjopen-2019-031951
- Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. J Clin Gastroenterol. 2017;51(6):467-78. doi: 10.1097/MCG.0000000000000854
- Shaheen NJ, Falk GW, Iyer P, et al. Diagnosis and Management of Barrett's Esophagus: An Updated ACG Guideline. Am JGastroenterol. 2022;117(4):559-87. doi: 10.14309/ajg.0000000000001680
- Mou WL, Feng MY, Hu LH. Eradication of Helicobacter Pylori Infections and GERD: A systematic review and meta-analysis. Turk J Gastroenterol. 2020;31(12):853-9. doi: 10.5152/tjg.2020.19699
- Zhao Y, Li Y, Hu J, et al. The Effect of Helicobacter pylori Eradication in Patients with Gastroesophageal Reflux Disease: A Meta-Analysis of Randomized Controlled Studies. Dig Dis. 2020;38(4):261-8. doi: 10.1159/000504086
- Wang XT, Zhang M, Chen CY, et al. Helicobacter pylori eradication and gastroesophageal reflux disease: a Meta-analysis. Zhonghua Nei Ke Za Zhi. 2016;55(9):710-6 (in Chinese). doi: 10.3760/cma.j.issn.0578-1426.2016.09.011
- Du YL, Duan RQ, Duan LP. Helicobacter pylori infection is associated with reduced risk of Barrett's esophagus: a meta-analysis and systematic review. BMC Gastroenterol. 2021;21(1):459. doi: 10.1186/s12876-021-02036-5
- Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390(10114):2769-78. doi: 10.1016/S0140-6736(17)32448-0
- Zhong Y, Zhang Z, Lin Y, et al. The Relationship Between Helicobacter pylori and Inflammatory Bowel Disease. Arch Iran Med. 2021;24(4):317-25. doi: 10.34172/aim.2021.44
- Shirzad-Aski H, Sima B, Kienesberger S, et al. Association Between Helicobacter pylori Colonization and Inflammatory Bowel Disease. J Clin Gastroenterol. 2021;55(5):380-92. doi: 10.1097/MCG.0000000000001415
- Wang L, Cao ZM, Zhang LL, et al. Helicobacter Pylori and Autoimmune Diseases: Involving Multiple Systems. Front Immunol. 2022;13:833424. doi: 10.3389/fimmu.2022.833424
- Yu Y, Zhu S, Li P, et al. Helicobacter pylori infection and inflammatory bowel disease: a crosstalk between upper and lower digestive tract. Cell Death Dis. 2018;9(10):961. doi: 10.1038/s41419-018-0982-2
- Murad HA. Does Helicobacter pylori eradication therapy trigger or protect against Crohn's disease? Acta Gastroenterol Belg. 2016;79(3):349-54.
- Lin KD, Chiu GF, Waljee AK, et al. Effects of Anti-Helicobacter pylori Therapy on Incidence of Autoimmune Diseases, Including Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019;17(10):1991-9. doi: 10.1016/j.cgh.2018.12.014
- Chen C, Xun P, Tsinovoi C, et al. Accumulated evidence on Helicobacter pylori infection and the risk of asthma: A meta-analysis. Ann Allergy Asthma Immunol. 2017;119(2):137-45.e2. doi: 10.1016/j.anai.2017.05.021
- Zuo ZT, Ma Y, Sun Y, et al. The Protective Effects of Helicobacter pylori Infection on Allergic Asthma. Int Arch Allergy Immunol. 2021;182(1):53-64. doi: 10.1159/000508330
- Оганов Р.Г., Симаненков В.И., Бакулин И.Г., и др. Коморбидная патология в клинической практике. Алгоритмы диагностики и лечения. Кардиоваскулярная терапия и профилактика. 2019;18(1):5-66 [Oganov RG, Simanenkov VI, Bakulin IG, et al. Comorbidities in clinical practice. Algorithms for diagnostics and treatment. Cardiovascular Therapy and Prevention. 2019;18(1):5-66 (in Russian)]. doi: 10.15829/1728-8800-2019-1-5-66
- Ширинский В.С., Ширинский И.В. Полиморбидность, старение иммунной системы и системное вялотекущее воспаление – вызов современной медицине. Медицинская иммунология. 2020;22(4):609-24 [Shirinsky VS, Shirinsky IV. Polymorbidity, ageing of immune system and low-grade systemic inflammation: a challenge for modern medicine. Medical Immunology (Russia). 2020;22(4):609-24 (in Russian)]. doi: 10.15789/1563-0625-PAO-2042
- Shah SC, Tepler A, Chung CP, et al. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology. 2021;161(5):1443-59. doi: 10.1053/j.gastro.2021.07.043
- Lesko LJ. Personalized medicine: elusive dream or imminent reality? Clin Pharmacol Ther. 2007;81(6):807-16. doi: 10.1038/sj.clpt.6100204
- Дедов И.И., Тюльпаков А.Н., Чехонин В.П., и др. Персонализированная медицина: современное состояние и перспективы. Вестник Российской академии медицинских наук. 2012;67(12):4-12 [Dedov II, Tyul'pakov AI, Chekhonin VP, et al. Personalized medicine: state-of-the-art and prospects. Annals of the Russian Academy of Medical Sciences. 2012;67(12):4-12 (in Russian)]. doi: 10.15690/vramn.v67i12.474
- Boffetta P, Collatuzzo G. Application of P4 (Predictive, Preventive, Personalized, Participatory) Approach to Occupational Medicine. Med Lav. 2022;113(1):e2022009. doi: 10.23749/mdl.v113i1.12622
- Zhang YF, Shi J, Yu HP, et al. Factors predicting survival in patients with proximal gastric carcinoma involving the esophagus. World J Gastroenterol. 2012;18(27):3602-9. doi: 10.3748/wjg.v18.i27.3602
- Matsuzaki J, Tsugawa H, Suzuki H. Precision Medicine Approaches to Prevent Gastric Cancer. Gut Liver. 2021;15(1):3-12. doi: 10.5009/gnl19257
- Uotani T, Miftahussurur M, Yamaoka Y. Effect of bacterial and host factors on Helicobacter pylori eradication therapy. Expert Opin Ther Targets. 2015;19(12):1637-50. doi: 10.1517/14728222.2015.1073261
- de Brito BB, da Silva FAF, Soares AS, et al. Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol. 2019;25(37):5578-89. doi: 10.3748/wjg.v25.i37.5578
- Matsumoto H, Shiotani A, Graham DY. Current and future treatment of Helicobacter pylori infections. Adv Exp Med Biol. 2019;1149:211-25. doi: 10.1007/5584_2019_367
- Park JY, Forman D, Waskito LA, et al. Epidemiology of Helicobacter pylor and CagA-Positive Infections and Global Variations in Gastric Cancer. Toxins (Basel). 2018;10(4):163. doi: 10.3390/toxins10040163
- Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype. World J Gastroenterol. 2014;20(21):6400-11. doi: 10.3748/wjg.v20.i21.6400